Use of danaparoid sodium (Orgaran®) as an alternative to heparin sodium during cardiopulmonary bypass: A clinical evaluation of six cases

Perfusion

Volumn 15, Issue 6, 2000, Pages 531-539

  Fernandes, P ^a   Mayer, R ^a   MacDonald, J L ^a   Cleland, A G ^a   Hay McKay, C ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APROTININ; BICARBONATE; BLOOD CLOTTING FACTOR 10A; DANAPAROID; GLUCOSE; HEMOGLOBIN; HEPARIN; KALLIKREIN; RINGER LACTATE SOLUTION;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA STENOSIS; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE SURGERY; HUMAN; INTRACARDIAC THROMBOSIS; LUNG EMBOLISM; MALE; MITRAL VALVE REGURGITATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0033670079     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/026765910001500610     Document Type: Article

References (7)

1. Heparin-induced thrombocytopenia
2. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Orgaran® 10172
3. New treatment options for heparin-induced thrombocytopenia
4. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia
5. 'Heparin-free' cardiopulmonary bypass: First reported use of heparinoid (Org. 10172) to provide anticoagulation for cardiopulmonary bypass
6. Heparin-induced thrombocytopenia: Cross-reactivity between standard heparin, low molecular weight heparin, daltepauin (Fragmin) and heparinoid, danaparoid (Orgaran)
7. Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia